The recently described anti-human immunodeficiency virus type 1 (HIV-1) human mAb PG9 and PG16 are cross-clade broadly neutralizing. Therefore, it can be postulated that the targeted epitope(s) are highly conserved among variants of the entire group M. We analysed the sensitivity to PG9 and PG16 of pseudotyped viruses carrying envelope glycoproteins from the viral quasispecies of three HIV-1 clade CRF01_AE-infected patients. The broad heterogeneity in sensitivity to PG9 and PG16, despite closely genetically related envelope glycoproteins issued from single individuals, allowed us to identify two gp120 cross-clade conserved residues, a lysine at position 168 in the V2 loop and an isoleucine at position 215 in the C2 region, whose substitutions were associated with resistance to PG9 and PG16. By site-directed mutagenesis, we confirmed both in clades B and CRF01_AE that the substitutions K168E and I215M have a major impact on PG9 and PG16 neutralization sensitivity of pseudotyped viruses.
INTRODUCTION
Elicitation of broadly neutralizing antibody (NAbs) responses is a key objective that should be reached for an efficient human immunodeficiency virus type 1 (HIV-1) vaccine (Barouch, 2008; Burton et al., 2004; Mascola, 2003; Mascola & Montefiori, 2010; . Indeed, NAbs have been shown to confer protection against infection challenge in animal models (Baba et al., 2000; Burton et al., 2011; Hessell et al., 2009a Hessell et al., , b, 2010 Mascola et al., 1999 Mascola et al., , 2000 Parren et al., 2001) . Until recently, only a handful of broadly neutralizing human mAbs have been isolated from HIV-1 clade B-infected individuals. Two of them, b12 and 2G12, recognize conformational epitopes located on the gp120 surface unit of the envelope spike, and two others, 2F5 and 4E10, recognize linear epitopes located on the membraneproximal external region (MPER) of the transmembrane unit gp41 (Mascola & Montefiori, 2010; . However, new approaches to recombinant human mAb isolation, developed over the past few years, have led to the identification of new exceptionally potent broadly neutralizing human mAbs (Bonsignori et al., 2011; Corti et al., 2010; Scheid et al., 2011; Walker et al., 2009 Walker et al., , 2011 Wu et al., 2010) . Among them, VRC01 and related mAbs (Corti et al., 2010; Scheid et al., 2011; Wu et al., 2010; Zhou et al., 2010) target the CD4-binding region of gp120, a domain already identified as a major neutralization component of the HIV-1 envelope (Binley et al., 2008; Li et al., 2007; . Others, PG9 and PG16 (Doores & Burton, 2010; Walker et al., 2009 ), CH01-CH04 (Bonsignori et al., 2011) and PGT141-145 (Walker et al., 2011) target the V1/V2 region, one of the most variable and highest glycosylated domains of gp120. These antibodies all show a preferential binding to the assembled trimeric spike over monomeric gp120, share specificity for an N-linked glycan at position 160 and are sensitive to changes in conserved V1/V2 and V3 residues. Among these, mAbs PG9 and PG16 demonstrated the most remarkable breadth since they neutralize 70-80 % of circulating HIV-1 isolates, suggesting that the targeted epitope(s) are highly conserved among variants of the entire group M. Recently, the structure of the V1/V2 region in complex with PG9 was reported (McLellan et al., 2011) . V1/V2 forms a four-stranded b-sheet domain, in which sequence diversity and glycosylation are largely segregated to strand-connecting loops. The V1/V2 site recognized by PG9 consists primarily of two glycans (N160 and N156/N173 glycans) and strand C, located at the edge of the sheet.
clones representative of the quasispecies present in motherinfant pairs infected by CRF01_AE viruses, and observed a broad range of sensitivity to PG9 and/or PG16 of maternal clones (Thenin et al., 2012) . Here, we took advantage of having closely genetically related gp120 variants to investigate the determinants conferring resistance to these two mAbs.
RESULTS AND DISCUSSION
Heterogeneity in sensitivity to PG9 and PG16 of closely related envelope glycoproteins issued from a single quasispecies
We selected 10 Env-pseudotyped viruses expressing the almost entire gp120 region issued from the viral quasispecies of three CRF01_AE-infected mothers (cases 0377, 0858 and 0978) described in a previous study (Thenin et al., 2012) . Sensitivity to PG9 and PG16 (from 10 to 0.005 mg ml
21
) was analysed in TZM-bl cells by measuring the luciferase activity 48 h post-infection (Thenin et al., 2012) . Five clones from case 0377 presented a broad and continuous range of sensitivity to PG9 (IC 50 range: 0.31-10 mg ml
) and to PG16 (IC 50 range: 1.98-10 mg ml 21 ) ( Table 1) . A broader range of sensitivity was observed in case 0978, clone 0978-M3 being resistant to PG9 and PG16 (IC 50 .10 mg ml
) whereas two other clones, 0978-M1 and 0978-M2, were highly sensitive (IC 50 range: 0.03-0.13 mg ml 21 ) (Table 1) . Similarly, two clones from case 0858 displayed peculiar patterns of neutralization: clone 0858-M1 was sensitive to neutralization by PG9 only (IC 50 : 0.29 mg ml
), but was resistant to PG16 (IC 50 .10 mg ml 21 ) whereas clone 0858-M2 was resistant to both mAbs (IC 50 .10 mg ml 21 ) ( Table 1) . These results showed the broad heterogeneity in sensitivity to PG9 and PG16 of closely genetically related envelope glycoproteins derived from single viral quasispecies.
Substitution K168E confers neutralization resistance to PG9 and PG16
Clone 0978-M3 from case 0978 was resistant to PG9 and PG16, whereas clones 0978-M1/M2 were highly sensitive to both mAbs. The alignment of Env amino acid sequences from these three clones revealed that clone 0978-M3 differed from clones 0978-M1/M2 by a unique substitution, glutamic acid (E) vs lysine (K), at position 170 in the V2 loop (corresponding to position 168 according to HxB2 Env; Fig. 1a ). Substitution K168E was previously shown to be involved in resistance to PG9 and PG16 of a reference B strain (Walker et al., 2009) . Analysis of complete Env sequences available from the Los Alamos database (http://www.hiv.lanl.govcontent/index) showed that the presence of a glutamic acid at position 168 is unusual, while a basic residue is found at this position in most of the sequences. Indeed, among 111 CRF01_AE and 698 clade B sequences, respectively, 100 (91.9 % lysine, 8.1 % arginine) and 94.7 % (84 % lysine, 10.7 % arginine) harbour a basic residue, whereas only 1.3 % of B sequences present a glutamic acid residue (Fig. 1b) . Similarly, among sequences from other subtypes, a basic residue is found in 99.1, 99.1, 100, 96.3 and 100 % of A, C, D, F and G sequences, respectively. Recently, this basic residue was shown to directly interact with PG9 in the reported structure of the V1/V2 region of two clade C strains in complex with this mAb (McLellan et al., 2011) .
To assess the impact of substitution K168E in a non-B naturally occurring variant, we created two mutant env genes by site-directed mutagenesis. We introduced substitution K168E in clone 0978-M2 (0978-M2 K168E) and the reverse substitution E168K in clone 0978-M3 (0978-M3 E168K) (Fig. 1c) . We produced pseudotyped viruses and then determined the neutralizing activity of PG9 and PG16 toward these mutants. Substitution E168K in the resistant clone 0978-M3 (0978-M3 E168K) resulted in a high sensitivity to both PG9 (IC 50 : 0.1 mg ml
21
) and PG16 (IC 50 : 0.03 mg ml
). In contrast, substitution K168E in the sensitive clone 0978-M2 (0978-M2 K168E) conferred resistance to both mAbs (IC 50 .10 mg ml 21 ; Fig. 1c and  1d ). Our results indicate that K168E had a major impact on PG9 and PG16 neutralization sensitivity, thus confirming in a non-B virus that an acidic residue or a basic residue at position 168 in the V2 loop is a key element determining the sensitivity to PG9 and PG16. Substitution I215M confers neutralization resistance to PG9 and PG16
As presented above, we observed peculiar patterns of neutralization for clones from case 0858: clone 0858-M1 was sensitive to PG9 but resistant to PG16, whereas clone 0858-M2 was resistant to both mAbs ( Table 1 ). The alignment of Env amino acid sequences revealed that these two clones differed only by two substitutions located in two constant regions. Clone 0858-M1 had isoleucine (I) at positions 215 (C2 region) and 475 (C5 region), whereas clone 0858-M2 had methionine (M) at these positions (Fig.  2a) . Analysis of sequences from the database indicated that 100 and 99.6 % of sequences from CRF01_AE and B viruses harbour an isoleucine at position 215, whereas only 0.1 % of B sequences had a M215, suggesting high conservation of an isoleucine at this position (Fig. 2b) . However, the conservation of an isoleucine at position 475 differed between the two subtypes. Indeed, 73 % of CRF01_AE sequences harbour an isoleucine and 20.7 % a methionine, whereas B sequences harbour mostly a M475 (98.4 %) and much less frequently a I475 (1.6 %). Similarly, in sequences belonging to other subtypes, the isoleucine at position 215 is highly conserved, with 99.1 and 97.6 % of A and C sequences, respectively, and 100 % of D, F and G sequences harbouring this residue, whereas the isoleucine at position 475 is less frequent, with only 3.4, 0.03 and 2.4 % of A, C and D sequences, respectively, and no F and G sequences containing this residue.
In order to analyse the contribution of each naturally occurring substitution (I215M and I475M) to the neutralization resistance of clone 0858-M2, we introduced the two reverse substitutions by site-directed mutagenesis in this ) by PG9 and PG16 of parental and mutant pseudotyped viruses.
clone (0858-M2 M215I and 0858-M2 M475I) (Fig. 2c) . Although the neutralization profiles of clones derived from case 0858 presented an unusual profile with a shallow slope and plateaus at ,100 %, a profile that was reported by others as linked to glycosylation at critical sites (Doores & Burton, 2010) , we found clearly that the substitution M215I in clone 0858-M2 (0858-M2 M215I) conferred sensitivity to PG9 (IC 50 : 0.71 mg ml 21 ), whereas the mutant 0858-M2 M475I remained highly resistant to PG9 (IC 50 .10 mg ml
; Fig. 2c and 2d) . These results suggest that the methionine at position 215 in the C2 domain has a major impact on the resistance to PG9 in a CRF01_AE clone.
To further assess the impact of M215 in resistance to PG9 and PG16, we analysed the sensitivity to both mAbs of a larger panel of Env-pseudotyped viruses derived from four additional CRF01_AE (0377-I1, 0978-M1, 0978-I3 and 1021-I1) and six clade B clones (5008CL2, 5008CL3, 5008CL8, 6006CL6, 11005CL3 and 11005CL7) issued from previous studies (Braibant et al., 2008; Chaillon et al., 2011; Thenin et al., 2012) . All these clones harboured an isoleucine at the position corresponding to 215 according to HxB2 Env numbering, and all were sensitive to both PG9 (IC 50 range: 0.03-3.31 mg ml 21 ) and PG16 (IC 50 range: 0.01-3.14 mg ml 21 ) (Fig. 3a, 3b and Table 2 ). By site-directed mutagenesis, we introduced substitution I215M in all clones, and found that I215M diminished the sensitivity of all clones to both PG9 and PG16, except that of clone 5008CL2 for PG9 ( Fig. 3a and 3b) . However, the magnitude of the effect appeared clearly clonedependent, illustrating the highly antigenic complexity of the HIV-1 glycoproteins (Table 2) . Collectively, both PG9 and PG16 IC 50 values were significantly lower for wild-type clones than for their mutated I215M counterparts (Wilcoxon matched-pairs signed rank test: P,0.01 and P50.01 for PG9 and PG16 IC 50 , respectively, Table 2 ).
Altogether these results indicate that a methionine at position 215 in the C2 domain has an impact on sensitivity to PG9 and PG16 in two distantly related HIV-1 clades. In addition to its contribution to the PG9/PG16 epitopes, the limited polymorphism across clades at this position might suggest that the residue at position 215 contributes to a functional domain.
Substitution I215M did not impact the global neutralization phenotype
We next wanted to assess if substitution I215M affects the overall conformation of the envelope glycoproteins by measuring its impact on sensitivity to neutralization by a panel of NAbs targeting different epitopes. Thus, we examined the sensitivity of both clade B and CRF01_AE clones to b12, a mAb targeting the CD4-binding region of gp120, and to 2F5 and 4E10 mAbs targeting the MPER of gp41. In addition, B clones were tested against 2G12 mAb recognizing a conformational glycan-dependent epitope on gp120. This last antibody was not used for the CRF01_AE clones since all of them lacked the N332 residue, which constitutes one of the essential N-glycosylation sites of the 2G12 epitope (Sanders et al., 2002; Scanlan et al., 2002) . Contrary to what we observed for PG9 and PG16, the mutation I215M did not lead to systematic changes in sensitivity to neutralization by any of the antibodies tested (Fig. 4a, 4b and Table 3 ). Concerning b12, the most resistant clones of each subtype (IC 50 .50 mg ml 21 ) remained resistant and the most sensitive clones (IC 50 ,10 mg ml 21 ) remained sensitive. Among the 11 tested clones, only two clade B clones, 5008CL3 and 5008CL8, displaying a moderate sensitivity to b12 were found to be more sensitive after introduction of substitution I215M (IC 50 : 9.87 vs 0.32 mg ml 21 and 6.13 vs 0.30 mg ml 21 , respectively). Collectively, the IC 50 of b12 toward wild-type or mutated clones were not significantly different (Wilcoxon matched-pairs signed rank test: P50.50).
Similarly, 2G12 sensitivity of B clones remained comparable (P50.25), with only one resistant clone, 5008CL3, which became moderately sensitive (IC 50 .50 vs 4.59 mg ml 21 ) ( Fig. 4b and Table 3 ). Both wild-type and mutated clones of each subtype were found to be highly sensitive to 2F5 (IC 50 range: ,0.10-0.69 mg ml
21
) and 4E10 (IC 50 range: ,0.10-1.93 mg ml 21 ). A trend towards a higher resistance of mutated clones compared to wild-type clones was nevertheless observed for 0377-I1, 0978-M1 and 1021-I1 CRF01-AE clones ( Fig. 4a and Table 3 ). However, the opposite was observed for 5008CL2, 11005CL3 and 11005CL7 clade B clones with a trend towards a higher sensitivity of the mutated counterparts ( Fig. 4b and Table  3 ). Collectively, comparing 2F5/4E10 IC 50 toward wildtype or mutated clones did not reveal any significant difference (P51.00 and 0.32, for 2F5 and 4E10 IC 50 , respectively).
Together these results indicate that, in contrast to what we observed for PG9 and PG16, a methionine or isoleucine residue at position 215 did not modulate the neutralization sensitivity by other mAbs, including antibodies targeting conformational-dependent epitopes on monomeric gp120. This suggested that the overall conformation of gp120 is not affected by the presence of a methionine at position 215.
Structure-function relationships
To try to understand the implication of M215 in resistance to PG9 and PG16, we modelled the three-dimensional structure of the gp120 from clone 0858-M2 in its monomeric and trimeric state. Because the V1/V2 loop structure was not elucidated in known structures of gp120, we used the recent X-ray data of the crystal structure of the V1/V2 domain in complex with the antigen-binding fragment (Fab) of PG9 (McLellan et al., 2011) to model the V1/V2 region of clone 0858-M2, independently of its gp120 core. We then grafted the obtained V1/V2 structure on a model of 0858-M2 gp120 core, to obtain a full monomeric model of 0858-M2 gp120. The trimeric model of 0858-M2 gp120 was reconstructed by superimposing three copies of the monomer onto the corresponding chains of a native gp120 trimer model in its unliganded state (Liu et al., 2008) . To locate the PG9/PG16 epitope on the gp120 trimer, we used an unliganded structure because previous studies have shown that both PG9 and PG16 binding to gp120 trimers is diminished by soluble CD4, suggesting that conformational changes induced by CD4 binding alters the epitope targeted by these antibodies (Walker et al., 2009 ).
The obtained three-dimensional 0858-M2 gp120 trimer revealed that M215 was located at the surface of a gp120 monomer in close spatial proximity to the PG9 epitope of a neighbouring monomer (Fig. 5) . In the context of the gp120 trimer, we can therefore hypothesize that the nature of the residue at position 215 of a given monomer may stabilize or destabilize the binding of PG9/PG16 to the epitope of a neighbouring monomer. This would be consistent with the fact that PG9/PG16 bind preferentially to the assembled trimeric spike ('quaternary epitope') over monomeric gp120. The M215 on a given monomer is also close to the stem of the V1/V2 domain of the same monomer, a region known to be involved in conformational changes after CD4 receptor binding. It may therefore be possible that the nature of the residue at position 215, close to the stem of the V1/V2 domain, could influence the ternary or quaternary conformation of gp120. An amino acid substitution at that position could then lead to local structural rearrangements and consequently could modify the conformation or exposure of the PG9/PG16 epitope. A drastic effect on the ternary structure of gp120 seems unlikely to occur given the absence of any systematic effect of the mutation M215I on neutralization by other neutralizing mAbs, including antibodies targeting conformational-dependent epitopes on monomeric gp120.
In conclusion, taking advantage of Env clones derived from closely related natural variants circulating in HIV-1-infected patients, we demonstrated the implication of two cross-clade-conserved residues in sensitivity to the broadly neutralizing mAbs PG9 and PG16. We confirm that an acidic residue or a basic residue at position 168 in the V2 loop is a key element determining the sensitivity to PG9 and PG16 (McLellan et al., 2011; Walker et al., 2009 ). In addition, we provide evidence of the involvement of a conserved residue at position 215 of the C2 region in the PG9/PG16 epitopes. Our study demonstrates that the screening of the sensitivity to mAbs neutralization of naturally occurring closely related variants issued from a patient's viral quasispecies is a useful strategy that may provide relevant data, complementary to those obtained through analysis of the sensitivity to mAbs of libraries of artificial mutants of a reference laboratory strain.
METHODS
Study population. We selected samples from mother-infant pairs enrolled in the 'Perinatal HIV Prevention Trial' cohort (Lallemant et al., 2000) , which were described in previous studies (Samleerat et al., 2008; Thenin et al., 2012) , and samples from long-term nonprogressor patients (Braibant et al., 2008; Chaillon et al., 2011) . Env clones corresponded to a 1.2 kb fragment of the V1/V5 region covering almost the entire HIV-1 env gp120 gene (from upstream V1 to downstream V5) previously cloned in pCR2.1 vector (Invitrogen). GenBank accession numbers are indicated in Table 1 and Fig. 3 .
Construction of chimeric env genes. In order to obtain complete gp160 env, we constructed chimeric env genes in an NL4.3 backbone as described previously (Braibant et al., 2010) . Briefly, the complete gp160 NL4.3 env gene was inserted into the EcoRI site of the pCR2.1 vector. Part of the env gene coding for V1/V5 regions was extracted from this construct using NdeI and MfeI restriction enzymes (New England BioLabs) and replaced by the corresponding gp120 sequence of interest excised from the pCR2.1 vector by digestion with the same enzymes. Chimeric env genes containing each gp120 sequence inserted in the NL4.3 backbone were then subcloned into the EcoRI site of the pCI expression vector (Promega).
Generation of env-pseudotyped viruses. Env-pseudotyped viruses were generated as described previously (Samleerat et al., 2009). 293T cells (3.5610 6 ) were co-transfected with 12 mg each pCI-env plasmid and 8 mg pNL4.3.LUC.R-E- (Connor et al., 1995) , using phosphate calcium (Invitrogen). Viral supernatants were collected 72 h later, purified by filtration (0.45 mm filter) and stored as aliquots at 280 uC. Viral infectivity was monitored by infection of 1610 4 TZM-bl cells with 100 ml serial fivefold dilutions of the viral supernatants in quadruplicate in the presence of 30 mg DEAE-dextran ml
21
. Infection levels were determined after 48 h, using the Bright Glo luciferase assay (Promega) and a Centro LB 960 luminometer (Berthold Technologies) to measure luciferase activity in cell lysates. Results with relative light unit (RLU) values .2.5 times the negative control (cells alone) were considered positive.
Neutralization and inhibition assay. Sensitivity to mAbs PG9, PG16, b12, 2G12, 2F5 and 4E10 were assessed in duplicate in TZM-bl cells. After titration, pseudotyped virus stocks were diluted to obtain 1000 TCID 50 ml 21 in growth medium. Aliquots of 25 ml were then incubated for 1 h at 37 uC with 75 ml of either threefold serial dilutions of PG9 and PG16 (10-0.005 mg ml 21 ; IAVI), or twofold serial dilutions of b12, 2G12, 2F5 and 4E10 (50-0.1 mg ml 21 ; Polymun Scientific). Then, 1610 4 TZM-bl cells were added to the virus/serum mixture in the presence of 30 mg DEAE-dextran ml 21 . Luciferase activity was measured 48 h after infection as described above. Results were expressed as mean values. IC 50 values were defined as the reciprocal of the serum dilution or antibody concentration required to reduce RLUs by 50 %.
Site-directed mutagenesis. Substitution of glutamic acid amino acid to lysine at position 168 (E168K) and the reverse substitution K168E were introduced by site-directed mutagenesis in clones 0978-M3 and 0978-M2 respectively. A Glu (GAG) was changed to a Lys (AAG) in clone 0978-M3 (0978-M3 E168K), and inversely, a Lys (AAG) was changed to a Glu (GAG) in clone 0978-M2 (0978-M2 K168E). Substitutions of methionine to isoleucine were introduced in clone 0858-M2 at position 215 (0858-M2 M215I) and 475 (0858-M2 M475I) by changing ATG to ATC. The reverse substitution of isoleucine to methionine at position 215 (I215M) was introduced in six clade B and four clade CRF01_AE Env clones, by changing ATA to ATG. DNA fragments containing the desired mutation within pCR2.1 Env clones were amplified by PCR with Phusion High Fidelity DNA Polymerase (BioLabs), using two nonoverlapping 59-phosphorylated primers. The PCR amplification conditions were one cycle at 98 uC for 30s followed by 35 cycles of 10 s at 98 uC, 30 s at 48 to 59 uC according to primers, and 30 s at 72 uC, and a final extension step of 72 uC for 10 min. Following amplification, the DNA products were treated with the DpnI endonuclease to digest the parental DNA template. The DNA products were then purified and ligated to themselves by using T4 Molecular modelling of gp120 monomer and trimer. A threedimensional model of the monomeric gp120 of 0858-M2 was built by comparative modelling using the SwissModel server at Expasy (www. expasy.ch) and a two-step procedure. First, gp120 core including V3 loop was modelled based on the structure of the HIV-1 JR-FL gp120 core protein complexed with CD4 and the X5 antibody (2b4c PDB accession name). Second, the V1/V2 loop of 0858-M2 was modelled independently based on the recently described X-ray structure of the V1/V2 domain of the CAP45 strain of HIV-1 complexed with neutralizing PG9 antibody (3u4e PDB code) (McLellan et al., 2011) . The resulting V1/V2 loop was then grafted at the corresponding insertion points in the 0858-M2 gp120 core. The full gp120 monomer was then energy-minimized without any constraints by 500 steps of conjugate gradient algorithm using Discover (InsightII software; Accelrys Inc). Quality of the final model was evaluated using various tools including Anolea and Gromos and found to be satisfactory. The trimer assembly of 0858-M2 gp120 was reconstructed by superimposing three copies of the 0858-M2 monomer onto the corresponding monomers of gp120 in their unliganded state of the HIV-1 gp120 trimer (HXB2R strain) (3dnn PDB code) using Pymol (www.pymol.org).
Disease progression due to dual infection in an HLA-B57-positive showing the location of Met 215 (blue) at the base of the bridging sheet, a residue which confers resistance of 0858-M2 strain to neutralization by PG9 antibody. The V1/V2 and V3 loop are coloured pale yellow and pale orange, respectively. The solvent-accessible molecular surface of gp120 is also shown with semi-transparent rendering. (b-c) Model of the trimer assembly of the 0858-M2 gp120 depicted with its molecular surface. Asparagine 156 and asparagine 160, which bear the glycan chains forming the major part of the V1/ V2 epitope involved in PG9 binding, are also shown in green for the front gp120 monomer. Interestingly, Met 215 of the next neighbour monomer appears to be in close spatial vicinity to the PG9 epitope region. In panel (c), the trimer was rotated by 906 around the x-axis.
The figure was prepared with Pymol (http://www.pymol.org).
